Swiss Approvals For Drugs With New Active Substances Surge In 2016
Swissmedic authorized 42 drugs containing new active pharmaceutical ingredients in 2016, compared with 28 the previous year. Seven of the products were approved under the fast-track procedure.
You may also be interested in...
Akcea Therapeutics has lowered its asking price in England for its antisense therapy for familial chylomicronaemia syndrome. It has also struck a pricing and reimbursement deal for the drug in Germany.
The sponsors of up to seven new drugs or vaccines will find out this week whether their products will soon be approved in the EU. The products include two vaccines from Sanofi and what is possibly the first generic rival to Bayer's Xarelto to be assessed by the European Medicines Agency.
Health technology assessment body NICE has published two final guidance documents that cover the use of AstraZeneca’s drug at different points in the treatment pathway for locally advanced or metastatic EGFR-positive non-small cell lung cancer.